

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28UNITED STATES DISTRICT COURT
NORTHERN DISTRICT OF CALIFORNIAERIN ALLEN,
Plaintiff,
v.
CONAGRA FOODS, INC.,
Defendant.

Case No. 13-cv-01279-JST

**ORDER DENYING MOTION TO
DISMISS AND, ALTERNATIVELY, TO
TRANSFER**

Re: Dkt. No. 17

Is Parkay Spray more like Pam® or liquid butter? That is the question posed by this consumer fraud action. Plaintiff Erin Allen alleges that Defendant ConAgra Foods, Inc. labels and markets Parkay Spray as “fat free” and “calorie free” even though a 226 gram bottle of the butter-flavored spray contains 93 grams of fat and 832 calories. ConAgra moves to dismiss on the grounds that federal regulations entitle food manufacturers to round down the fat and calorie content of their products when a single serving contains less than 0.5 grams of fat and 5 calories. Plaintiff alleges that ConAgra uses artificially — and unlawfully — small serving sizes intended for non-stick cooking sprays such as Pam in order to round its sprayable butter down to zero.

I. FACTUAL ALLEGATIONS

Plaintiff Erin Allen filed this case on March 21, 2013, asserting seven causes of action on behalf of a nationwide class of consumers, and a California subclass, against Defendant ConAgra Foods, Inc. ECF No. 1 (“Compl.”). Plaintiff asserts claims for unjust enrichment and restitution, fraud by concealment, breach of express warranty, intentional misrepresentation, and violation of the consumer protection statutes of the fifty states and the District of Columbia, excluding Ohio. On behalf of the California class, Plaintiff also asserts causes of action for violation of California’s Consumer Legal Remedies Act, Cal. Civ. Code § 1750, et seq. (“CLRA”), and the Unfair

1 Competition Law, Cal. Bus. & Prof. Code § 17200, et seq. ("UCL").

2 According to the Complaint, Conagra sells and markets Parkay Spray, a liquid butter
3 substitute, as having “zero fat” and ”zero calories.” Compl. ¶ 3. An eight-ounce, 226 gram bottle
4 of Parkay Spray contains 832 calories and 93 grams of fat. Id.¶¶ 4, 28. The Complaint alleges the
5 fat free and calorie free claims are false and misleading, and that Parkay Spray’s product label lists
6 the artificially small serving sizes of one spray, or 0.2 grams, for cooking and five sprays, or 1.0
7 grams, for topping. Id.¶¶ 6, 28. Those serving sizes amount to 1,130 one-spray servings per
8 eight-ounce bottle or 226 five-spray servings. The Complaint also alleges that the Parkay Spray
9 bottle lists as ingredients soybean oil and buttermilk without providing an asterisk and language
10 disclosing the presence of fat in those ingredients in violation of regulations promulgated by the
11 Federal Food and Drug Administration (“FDA”). Id.¶¶ 33–34.

12 The Complaint alleges that ConAgra knew or should have known that Parkay Spray
13 labeling and marketing are misleading and engender confusion among consumers. Id. ¶ 36. As
14 evidence of such confusion, plaintiff alleges that “[t]he internet is replete with complaints echoing
15 that of the named plaintiff. For example, a contributor to the website ‘that’s fit’ writes, ‘This issue
16 makes me furious — so often products that are full of fat, and even transfats, designate completely
17 ridiculous serving sizes, then “round” the fat down to zero. Often, they won’t even have on the
18 label anywhere what the actual fat content is. So people think there’s no fat when there’s a ton.’”
19 Id. According to another contributor, “[t]his is exactly what the marketing of this product was
20 supposed to do — make you believe . . . that we are consuming less calories than we actually
21 are.” Id.

22 Plaintiff Allen alleges that she is a reasonably diligent consumer who, looking for fat free
23 and calorie free alternatives to butter, purchased Parkay Spray in reliance on the statements on the
24 bottle and in ConAgra’s marketing. Id. ¶¶ 40–41. According to Plaintiff, she paid a premium for
25 Parkay Spray that she otherwise would not have paid had she known that it contained 93 grams of
26 fat and 832 calories per bottle. Id.¶¶ 44–46. She also alleges that, because it is not fat and calorie
27 free, Parkay Spray is worth less than what Plaintiff and members of the proposed class paid for it,
28

1 and that she and the class were induced to and did purchase the product instead of competing
2 products based on the false statements and misrepresentations. Id. ¶¶ 47–48.

3 **II. REQUESTS FOR JUDICIAL NOTICE**

4 Although a court’s review on a motion to dismiss is generally limited to the allegations in
5 the complaint, Lee v. City of Los Angeles, 250 F.3d 668, 688 (9th Cir. 2001), the court may
6 properly take judicial notice of material attached to the complaint and of matters in the public
7 record pursuant to Federal Rule of Evidence 201(b). See, e.g., Castillo-Villagra v. INS, 972 F.2d
8 1017, 1026 (9th Cir. 1992). The “incorporation by reference” doctrine applies when a “plaintiff’s
9 claim depends on the contents of a document, the defendant attaches the document to its motion to
10 dismiss, and the parties do not dispute the authenticity of the document, even though the plaintiff
11 does not explicitly allege the contents of that document in the complaint.” Knieval v. ESPN, 393
12 F.3d 1068, 1076 (9th Cir. 2005). A court may thus take judicial notice of matters of public record
13 without converting a motion to dismiss into a motion for summary judgment, but it may not take
14 judicial notice of a fact that is subject to reasonable dispute. Lee v. City of Los Angeles, 250 F.3d
15 at 689. A court “shall take judicial notice if requested by a party and supplied with the necessary
16 information.” Fed. R. Evid. 201(d). See Sato v. Wachovia Mortg., FSB, No. 11-cv-00810-EJD,
17 2011 WL 2784567, at *2 (N.D. Cal. July 13, 2011).

18 With its motion to dismiss, ConAgra seeks judicial notice of a reproduction of Parkay
19 Spray’s current product and nutrition labels. ECF No. 20, Ex. A. With the opposition, Plaintiff
20 requests judicial notice of FDA “Inspection Guidelines” concerning serving sizes for food
21 products and a copy of ConAgra’s Parkay Spray web page. ECF No. 25, Exs. B, C. The parties
22 also submitted copies of various FDA regulations. No party opposes judicial notice of these
23 documents, and the court finds them appropriate for judicial notice as documents incorporated by
24 reference by the complaint and otherwise documents in the public record not reasonably subject to
25 dispute because their accuracy can readily be determined from sources whose accuracy cannot
26 reasonably be questioned. The requests for judicial notice are therefore GRANTED.

27
28

1 **III. LEGAL STANDARDS**

2 On a motion to dismiss, the court accepts the material facts alleged in the complaint,
3 together with reasonable inferences to be drawn from those facts, as true. Navarro v. Block, 250
4 F.3d 729, 732 (9th Cir. 2001). However, “the tenet that a court must accept a complaint’s
5 allegations as true is inapplicable to threadbare recitals of a cause of action’s elements, supported
6 by mere conclusory statements.” Ashcroft v. Iqbal, 556 U.S. 662, 678 (2009). To be entitled to
7 the presumption of truth, a complaint’s allegations “must contain sufficient allegations of
8 underlying facts to give fair notice and to enable the opposing party to defend itself effectively.”
9 Starr v. Baca, 652 F.3d 1202, 1216 (9th Cir. 2011), cert. den’d, --- U.S. ----, 132 S.Ct. 2101
10 (2012).

11 In addition, to survive a motion to dismiss, a plaintiff must plead “enough facts to state a
12 claim to relief that is plausible on its face.” Bell Atlantic Corp. v. Twombly, 550 U.S. 544, 570
13 (2007). Plausibility does not mean probability, but it requires “more than a sheer possibility that a
14 defendant has acted unlawfully.” Iqbal, 556 U.S. at 678. “A claim has facial plausibility when the
15 plaintiff pleads factual content that allows the court to draw the reasonable inference that the
16 defendant is liable for the misconduct alleged.” Id. In the Ninth Circuit, “[i]f there are two
17 alternative explanations, one advanced by defendant and the other advanced by plaintiff, both of
18 which are plausible, plaintiff’s complaint survives a motion to dismiss under Rule 12(b)(6).
19 Plaintiff’s complaint may be dismissed only when defendant’s plausible alternative explanation is
20 so convincing that plaintiff’s explanation is implausible.” Starr, 652 F.3d at 1216 (original
21 emphasis).

22 Fraud claims are subject to a heightened pleading standard. “In alleging fraud or mistake,
23 a party must state with particularity the circumstances constituting fraud or mistake. Fed. R. Civ.
24 P. 9(b). The allegations must be specific enough to give a defendant notice of the particular
25 misconduct alleged to constitute the fraud such that the defendant may defend against the charge.
26 Semegen v. Weidner, 780 F.2d 727, 731 (9th Cir. 1985). In general, allegations sounding in fraud
27 must contain “an account of the time, place, and specific content of the false representations as
28

1 well as the identities of the parties to the misrepresentations.” Swartz v. KPMG LLP, 476 F.3d
2 756, 765 (9th Cir. 2007).

3 **IV. ANALYSIS**

4 ConAgra moves to dismiss the Complaint as expressly preempted by the Food, Drug, and
5 Cosmetic Act (“FDCA”), 21 U.S.C. § 301, et seq., which vests the FDA with food labeling
6 authority, 21 U.S.C. § 393, and the Nutrition Labeling and Education Act of 1990 (“NLEA”), 21
7 U.S.C. § 343-1, which amended the FDCA and sets forth “uniform national standards for the
8 nutritional claims the required nutrient information displayed on food labels,” 1990 U.S.C.C.A.N.
9 3336, 3342; Pub. L. No. 101-535, 104 Stat. 2353 (1990), amending 21 U.S.C. § 343. In addition,
10 ConAgra moves to dismiss pursuant to the primary jurisdiction doctrine. Alternatively, ConAgra
11 moves to transfer this action to the District of Nebraska, where a similar case was filed against it
12 and then dismissed.

13 **A. Federal Preemption**

14 Federal law preempts a lawsuit based on state law claims when (1) Congress enacts a
15 statute that explicitly preempts state law; (2) federal law occupies a legislative field to such an
16 extent that it is reasonable to conclude that Congress left no room for state regulation in that field;
17 or (3) state law actually conflicts with federal law. See Cipollone v. Liggett Grp., Inc., 505 U.S.
18 504, 516 (1992). “[T]he purpose of Congress is the ultimate touchstone in every pre-emption
19 case.” Wyeth v. Levine, 555 U.S. 555, 565 (2009). In all cases, “and particularly in those in
20 which Congress has ‘legislated . . . in a field which the States have traditionally occupied,’ . . . we
21 ‘start with the assumption that the historic police powers of the States were not to be superseded
22 by the Federal Act unless that was the clear and manifest purpose of Congress.’” Id. (quoting
23 Medtronic, Inc. v. Lohr, 518 U.S. 470, 485 (1996)).

24 The NLEA expressly preempts “any requirement for the labeling of food of the type
25 required by” various labeling provisions that is not identical to those requirements, as well as “any
26 requirement for nutrition labeling of food” and any requirement respecting nutrient claims that are
27 not identical to the requirements of several FDCA provisions. 21 U.S.C. § 343-1(a)(2)–(5). Of
28

1 particular relevance here, the preemption clause applies to 21 U.S.C. § 343(q), titled “Nutrition
2 Information,” and § 343(r), titled “Nutrition Levels and Health-Related Claims.” Section 343(q)
3 requires food manufacturers to disclose the amount of fat and calories in their products. Section
4 343(r) establishes uniform requirements for nutrient content claims.

5 Pursuant to the FDCA and the NLEA, and in particular to FDCA sections 343(q) and (r),
6 the FDA promulgated comprehensive labeling requirements, including those at 21 C.F.R. §§ 101.9
7 (fat and calorie content on nutrition label), 101.12 (reference amounts customarily consumed per
8 eating occasion), 101.13 (nutrient content claims), 101.60 (calorie content claims), and 101.62 (fat
9 content claims). Plaintiff concedes that those regulations impose express requirements on food
10 labeling relevant to this case; indeed, Plaintiff’s causes of action are premised on ConAgra’s
11 labeling and marketing of Parkay Spray in a manner that Plaintiff alleges both violates FDA
12 regulations and misleads consumers in violation of state law.

13 Plaintiff argues that the Complaint seeks to impose requirements on ConAgra’s labeling
14 and marketing of Parkay Spray that are identical to, and do not deviate from, the requirements of
15 the FDCA, NLEA, and the relevant FDA regulations. If Plaintiff is correct, the Complaint is not
16 preempted because Plaintiff’s suit does not threaten to impose any additional or different
17 requirements on ConAgra than those already required by federal law. See H.R. Rep. No. 538,
18 1990 U.S.C.C.A.N. 3336, 3337 (noting that NLEA will “prevent State and local governments
19 from adopting inconsistent requirements with respect to the labeling of nutrients or with respect to
20 the claims that may be made about the nutrients in foods. However, these governmental entities
21 are explicitly permitted to enforce Federal requirements with respect to nutrition labeling.”)
22 (emphasis added); Chacanaca v. Quaker Oats Co., 752 F.Supp.2d 1111, 1118 (N.D.Cal. 2010)
23 (“Where a requirement imposed by state law effectively parallels or mirrors the relevant sections
24 of the NLEA, courts have repeatedly refused to find preemption.”) (citing New York State Rest.
25 Ass’n v. New York City Bd. of Health, 556 F.3d 114, 123 (2d Cir.2009); Jones v. ConAgra Foods,
26 Inc., No. 12-cv-01633-CRB, 2012 WL 6569393, at *4 (N.D. Cal. Dec. 17, 2012) (citing Final
27 Rule, 60 Fed. Reg. 57076, 57120 (Nov. 13, 1995) (“[I]f the State requirement does the same thing
28

1 that the Federal law does . . . then it is effectively the same requirement as the Federal requirement
2 [T]he only State requirements that are subject to preemption are those that are affirmatively
3 different from the Federal requirements on matters that are covered by section 403A(a) of the act
4 [21 U.S.C. § 343-1(a)].”). See also Lohr, 518 U.S. at 471 (FDCA “does not preempt State or
5 local requirements that are equal to, or substantially identical to, requirements imposed by or
6 under the act” in the medical device context).

7 Plaintiff’s claims are based on five alleged violations of FDA regulations: (1) zero calorie
8 nutrition labeling (§ 101.9(c)(1)), (2) zero fat nutrition labeling (§ 101.9(c)(2)), (3) zero calorie
9 content claims (§ 101.60), and (4) “fat free” content claims (§ 101.62). In addition, Plaintiff
10 alleges Parkay Spray violates the requirement in 21 C.F.R. § 101.62(b)(ii) that permits “fat free”
11 labeling provided “[t]he food contains no added ingredient that is a fat or is generally understood
12 by consumers to contain fat unless the listing of the ingredient in the ingredient statement is
13 followed by an asterisk that refers to the statement below the list of ingredients, which states ‘adds
14 a trivial amount of fat,’ ‘adds a negligible amount of fat,’ or ‘adds a dietarily insignificant amount
15 of fat.’”

16 At the core of the parties’ dispute over the "zero fat" and "zero calorie" label and nutrition
17 claims is the serving size specified on the Parkay Spray bottle. Each of the alleged violations of
18 federal regulations stems directly from the serving size table for adults established at 21 C.F.R.
19 § 101.12(b)(2), which sets forth the “reference amounts customarily consumed per eating
20 occasion” from which the FDA’s other labeling and content claim regulations flow. ConAgra
21 argues that the one-spray, 0.2 gram, and five-spray, 1.0 gram serving sizes on the bottle are
22 consistent with the serving size table because, under the heading “Fats and Oils,” the reference
23 amount for “spray types” is 0.25 grams. If, as ConAgra argues, the “spray types” reference
24 amount applies to Parkay Spray, then the serving sizes on the bottle are permitted by the
25 regulations. In turn, that serving size renders the fractional amount of fat in a single spray, and in
26 five sprays, of Parkay Spray below 0.5 grams, which, pursuant to 21 C.F.R. § 101.9(c)(2), means
27 that ConAgra is required to round the fat content down to zero grams of fat per serving on the
28

1 nutrition label. ConAgra would also be permitted to claim that Parkay Spray is “fat free” on the
2 product label pursuant to 21 C.F.R. § 101.62(b)(1)(i). Similarly, that serving size results in less
3 than five calories per serving, which, pursuant to § 101.9(c)(1), means that ConAgra would be
4 permitted to round the calorie count down to zero calories per serving on its nutrition label, and,
5 pursuant to 21 C.F.R. § 101.60(b)(1)(i), ConAgra would be permitted to claim that Parkay Spray
6 is calorie free on its product label. Since Plaintiff’s claims stem from the serving size definition
7 on the Parkay Spray bottle, if ConAgra’s serving size is properly defined under FDA regulations,
8 Plaintiff’s challenge to the serving size would be expressly preempted by the NLEA’s preemption
9 clause.

10 However, Plaintiff argues that the reference amount that applies to Parkay Spray is not the
11 0.25 gram reference amount for “spray type” fats and oils, but the amount for products in the
12 “butter, margarine, oil, shortening” category, which is also under the heading “Fats and Oils” in
13 the table at section 101.12(b)(2). That reference amount is one tablespoon, which Plaintiff
14 calculates as fifty times the reference amount for “spray type” fats and oils. If Plaintiff is correct,
15 ConAgra is not permitted to round down Parkay Spray’s fat and calorie content because the fat
16 content and calorie count per serving exceeds the 0.5 grams of fat and five calorie thresholds.

17 The dispute, then, is over whether Parkay Spray belongs in the “spray type” fat or oil
18 category, or the “butter, margarine, oil, shortening” category. In answering that question, the court
19 first looks to the text of the statute.

20 **1. Plaintiff Has Adequately Alleged That Parkay Spray Is A Liquid**
21 **Butter Substitute**

22 The FDCA requires that food product labels provide “the serving size which is an amount
23 customarily consumed and which is expressed in a common household measure that is appropriate
24 to the food.” *Id.* § 343(q)(1)(A)(i). Alternatively, “if the use of the food is not typically expressed
25 in a serving size,” the label must provide “the common household unit of measure that expresses
26 the serving size of the food.” *Id.* § 343(q)(1)(A)(ii). The nutrition label must also state the total
27 number of calories, but that number may be “derived from the total fat, in each serving size or
28 other unit of measure of the food.” *Id.* § 343(q)(1)(C)(ii). The corresponding regulation states:

1 “serving size declared on a product label shall be determined from the ‘Reference Amounts
2 Customarily Consumed Per Eating Occasion * * * *’ (reference amounts) that appear in
3 § 101.12(b) using the procedures described below.” Id. § 101.9(b)(2).

4 The table at 21 C.F.R. § 101.9(b)(2) establishes the reference amount for “Butter,
5 margarine, oil, shortening” as one tablespoon. The reference amount for “Spray type” fats and oils
6 is 0.2 grams. The regulation explains that “FDA calculated the reference amounts for persons 4
7 years of age or older to reflect the amount of food customarily consumed per eating occasion by
8 persons in this population group. These reference amounts are based on data set forth in
9 appropriate national food consumption surveys.” Id. § 101.12(a)(1). “The reference amount is
10 based on the major intended use of the food (e.g., milk as a beverage and not as an addition to
11 cereal).” Id. § 101.12(a)(7). The reference amounts provided in the table are mandatory. Id.
12 § 101.12(b). Further, “The reference amount for an imitation or substitute food or altered food,
13 such as a ‘low calorie’ version, shall be the same as for the food for which it is offered as a
14 substitute.” Id. § 101.12(d).

15 The table also contains a column titled “Label Statement,” which “are meant to provide
16 guidance to manufacturers on the presentation of serving size information on the label, but they
17 are not required.” Id. § 101.12 n. 5. “Manufacturers should use the description of a unit that is
18 most appropriate for the specific product (e.g., sandwich for sandwiches, cookie for cookies, and
19 bar for ice cream bars). The guidance provided is for the label statement of products in ready-to-
20 serve or almost ready-to-serve form. The guidance does not apply to the products which require
21 further preparation for consumption (e.g., dry mixes, concentrates) unless specifically stated in the
22 product category, reference amount, or label statement column that it is for these forms of the
23 product.” Id. The label statement for butter products reads: “1 tbsp (___ g); 1 tbsp (15 mL).”
24 The label statement for spray type fats and oils reads: “About ___ seconds spray (___ g).” Id.
25 § 101.12(b)(2).

26 ConAgra asserts the circular argument that Parkay Spray belongs under the product
27 category of spray type fats and oils because “Parkay Spray is a spray.” ECF No. 27 (“Reply”)
28

1 p. 3. Parkay Spray is not “liquid butter,” ConAgra argues, because the FDCA defines butter as
 2 containing milk or cream, or both. See 21 U.S.C. § 321a. But the reference table category for
 3 butter includes margarine, oil, and shortening along with it, and it also provides that the reference
 4 amount for imitation and substitute products “shall be the same as for the food for which it is
 5 offered as a substitute.” 21 C.F.R. § 101.12(d). Imitation butter, which may contain neither milk
 6 nor cream, therefore belongs in the same reference amount category as butter.

7 Next, ConAgra argues that the reference amount for spray type fats and oils is more
 8 specific than the more general reference amount for butter, margarine, oil, and shortening, and that
 9 specific reference amounts trump general reference amounts. Reply p. 4 (citing Barboza v.
 10 California Ass’n Professional Firefighters, 651 F.3d 1073, 1077 (9th Cir. 2011)). That rule of
 11 regulatory interpretation, however, applies only where regulations are in conflict. See, e.g.,
 12 Barboza, 651 F.3d at 1077 (resolving circular references in ERISA that are irreconcilable absent
 13 further interpretation by relying on specific “exception” to general rule). Nothing in the text of the
 14 regulation here reveals a conflict. The table lists food product categories; whether Parkay Spray
 15 belongs under one or another is properly a question of regulatory interpretation not because the
 16 regulation contains conflicting provisions, but because it requires the application of facts to law, a
 17 familiar judicial exercise. Moreover, even if the fat and oil product categories conflict with each
 18 other, nothing in the table, or in any other FDA regulations, suggests that the “spray type”
 19 category is more specific than any other.

20 ConAgra also argues that its definition of servings as “one spray” and “five sprays” on the
 21 Parkay Spray bottle is dispositive. ECF No. 17 at 5 (“Any effort by Plaintiff to argue that the
 22 serving sizes are artificially small, moreover, is inconsistent with the FDA regulations.”). But
 23 since Plaintiff alleges that the serving sizes shown on the Parkay Spray bottle do not comply with
 24 the relevant regulations, see Compl. ¶ 6; 21 C.F.R. §§ 101.9(b)(2) and 101.12(b), ConAgra’s claim
 25 to the contrary does not mean the claim is preempted, but only that there is a live claim between
 26 the parties. Indeed, it is worth noting here that an eight-ounce Parkay Spray bottle claims to
 27 contain 1,130 single spray servings. Putting aside the difficulty of imagining anyone obtaining
 28

1 over 1,000 sprays from an eight-ounce bottle of liquid, Plaintiff alleges that Parkay Spray is not
2 typically dispensed in a single spray. Relying on ConAgra’s own serving size definitions would
3 defeat the purpose of the regulations’ insistence on objective and uniform food labeling.

4 ConAgra next argues that the label statement guidance for spray type fats and oils, which
5 is expressed as servings per second of spraying, is inapplicable to Parkay Spray, both because it is
6 non-binding and because Parkay Spray is a manual pump and not an aerosol spray. Once again,
7 however, ConAgra’s argument begs the question. Plaintiff plausibly alleges that the reason the
8 FDA’s label statement guidance does not apply is not because Parkay uses a pump, but Parkay is
9 labeled and used as a topping and butter-substitute – not a cooking spray.

10 Based solely on the FDCA and FDA regulations, plaintiff adequately alleges that imitation
11 butter, whether it is liquid or solid, and whether it is packaged in a spray pump, a squeeze bottle,
12 or something else, is subject to the serving size requirements of the fat and oil product category
13 “butter, margarine, oil, shortening.”

14 Plaintiff marshals substantial support for its allegation that Parkay Spray should be
15 categorized with other imitation butter products. According to the Complaint, the product label,
16 and Parkay Spray’s website, the product is a substitute for butter that shares butter’s “Fresh and
17 Creamy Taste” without the negative health consequences. The front of the Parkay Spray bottle is
18 an image of corn on the cob. The serving sizes on the bottle are for cooking and for topping. And
19 at the bottom of the bottle, the back label invites customers to visit the Parkay Spray website “for
20 delicious recipes.”

21 Similarly, the website advertises Parkay “Spreads.” There, customers can choose from the
22 Parkay Original Spread, which “turns all your family’s favorite foods into comfort foods”; Parkay
23 Light Spread, which “has half the fat and calories of butter and regular margarines”; Parkay
24 Original Sticks, which are manufactured like sticks of butter; Parkay Squeeze, “the convenient,
25 family-friendly way to put the buttery taste of Parkay on favorites, like corn-on-the-cob, waffles,
26 and pancakes”; and, finally, Parkay Spray, which is described as follows: “Get the buttery taste of
27 Parkay on all your favorite foods with zero calories per serving! It’s the guilt-free way to top
28

1 vegetables, potatoes, poultry, and so much more. Plus, Parkay Spray has 0g of trans fat per
2 serving.” ECF No. 25-3, available at <http://www.parkay.com/out-spreads.jsp>.

3 These examples are directly related to the FDA’s admonition that “the serving size [] is an
4 amount customarily consumed and which is expressed in a common household measure that is
5 appropriate to the food.” 21 C.F.R. § 343(q)(1)(A)(i). Accordingly, FDA calculated the serving
6 sizes “based on data set forth in appropriate national food consumption surveys.” 21 C.F.R. §
7 101.12(a)(1). “The reference amount is based on the major intended use of the food (e.g., milk as
8 a beverage and not as an addition to cereal).” Id. § 101.12(a)(7). Plaintiff has alleges that Parkay
9 Spray is intended to be used as butter, and that customers use it that way. If Plaintiff is correct,
10 then the correct reference amount is the reference amount for butter.

11 Though the court finds the regulations unambiguous, even if they required further
12 interpretation, FDA’s reading of its own rule, which is entitled to “substantial deference,” Riegel
13 v. Medtronic, Inc., 552 U.S. 312, 328 (2008) (interpreting FDCA and Medical Devices Act),
14 indicates that the “spray type” category was not meant for products like Parkay Spray. The FDA
15 has not squarely addressed the reference amount for Parkay Spray, but it has published guidance
16 regarding the products to which each category in the reference table applies. The FDA published
17 its “Guide to Nutrition Labeling and Education Act (NLEA) Requirements” in August 1994.¹ The
18 preamble provides: “The following information is provided as assistance for reviewing food labels
19 for compliance with new requirements for nutrition labeling and nutrient claims.” Attachment 26
20 to the Guide² lists each product category found in the reference amount table followed by each
21 product to which the category applies. Under “Fats and Oils,” the products listed for the “butter,
22 margarine, oil, shortening” category are: “All types of butter and margarine (regular, diet, liquid,
23 and whipped); spreads; oils; and shortenings.” By contrast, the product listing for the “spray
24

25 _____
26 ¹ The guide is available on the FDA’s website at
<http://www.fda.gov/ICECI/Inspections/InspectionGuides/ucm074948.htm>.

27 ² Attachment 26 is available at available at
28 <http://www.fda.gov/ICECI/Inspections/InspectionGuides/ucm114704.htm>.

1 types” category reads: “Nonstick cooking sprays (e.g., Pam).”

2 ConAgra argues that the spray type category is not limited to the products listed in
3 Attachment 26, and that Pam is only an example that does not exclude the possibility that Parkay
4 Spray belongs in the same category. That argument misreads the table. Pam is listed as an
5 example of “nonstick cooking sprays.” Footnote one to Attachment 26 states: “Each product
6 category includes all forms of products which belong to the category, e.g., ready-to-serve, almost
7 ready-to-serve i.e. heat and serve, brown and serve), dry mix, concentrate, dough and butter.”
8 Liquid butter, and substitute liquid butter, as well as spreads, belong in the butter product
9 category.

10 The court concludes that Plaintiff has adequately alleged that the serving size listed on
11 Parkay Spray bottles is the wrong serving size. Because Plaintiff does not seek to impose
12 requirements that differ from those imposed by the FDCA, NLEA, and FDA regulations,
13 Plaintiff’s claims are not preempted. See Lohr, 518 U.S. at 471 (FDCA “does not preempt State
14 or local requirements that are equal to, or substantially identical to, requirements imposed by or
15 under the act” in the medical device context).

16 **2. Plaintiff’s Claims Do Not Impermissibly Arise Under The FDCA**

17 ConAgra also argues that Plaintiff’s claims are preempted by the FDCA because plaintiffs
18 are impermissibly suing to enforce it.

19 There is no private right of action under the FDCA. See 21 U.S.C. 337(a) (“[A]ll []
20 proceedings for the enforcement, or to restrain violations, of this chapter shall be by and in the
21 name of the United States.”). However, “[t]he existence of the FDCA does not completely
22 preclude injured parties from asserting claims of fraud or false advertising. Other legislation, state
23 and federal remains in effect to protect consumers from false and deceptive prescription drug
24 advertising.” In re Epogen & Aranesp Off-Label Mkt’g & Sales Practice Litig., 590 F.Supp.2d
25 1282, 1290 (C.D.Cal.2008), quoted with approval in Jackson v. Balanced Health Products, Inc., C
26 08-05584 CW, 2009 WL 1625944 (N.D. Cal. June 10, 2009). Thus, Plaintiffs must navigate a
27 “narrow gap” to escape preemption: they must sue for conduct that specifically violates the FDCA
28

1 to avoid express preemption, but they cannot sue because the conduct violates the FDCA. Perez
2 v. Nidek Co., Ltd., 711 F.3d 1109, 1120 (9th Cir. 2013) (quoting In re Medtronic, Inc., Sprint
3 Fidelis Leads Products Liability Litig., 623 F.3d 1200, 1204 (8th Cir. 2010).

4 Plaintiff's claims thread this gap. The Complaint alleges that Parkay Spray's labels and
5 marketing are false and misleading because they advertise that Parkay Spray is "fat free" and
6 "calorie free" when it is not. Plaintiff's allegation that Defendant's statements violate FDA
7 regulations as written is necessary for her claims to avoid preemption, but not necessary for her to
8 establish the underlying state law causes of action. The FDCA therefore does not preclude
9 Plaintiff from bringing those claims. See, e.g., Jackson v. Balanced Health Products, Inc., No. 08-
10 cv-05584-CW, 2009 WL 1625944, at *4 (N.D. Cal. June 10, 2009) (no preemption where
11 "Plaintiffs' claims are based on false and misleading advertising and mislabeling under the
12 Sherman Law."). To hold otherwise would improperly invade "the historic primacy of state
13 regulation of matters of health and safety." Lohr, 518 U.S. at 485.

14 Because Plaintiff's state law claims do not threaten to impose requirements on ConAgra
15 that differ from those required by FDA regulations, ConAgra's motion to dismiss on the basis of
16 preemption is hereby DENIED.

17 **B. Primary Jurisdiction**

18 ConAgra moves to dismiss on the separate basis that Plaintiff's claims depend on federal
19 regulations that are within FDA's primary jurisdiction. Per ConAgra, "Plaintiff's claims ask this
20 court (and ultimately a jury) to insert themselves into an ongoing field of regulatory activity."
21 ECF No. 17 ("Opp.") p. 8.

22 The doctrine of primary jurisdiction applies in a "limited set of circumstances." Clark v.
23 Time Warner Cable, 523 F.3d 1110, 1114 (9th Cir. 2008). It permits courts to stay proceedings, or
24 to dismiss a complaint without prejudice, pending the resolution of an issue within the "special
25 competence of an administrative agency." The doctrine is prudential; it applies when "a court
26 determines that an otherwise cognizable claim implicates technical and policy questions that
27 should be addressed in the first instance by the agency with regulatory authority over the relevant
28

1 industry rather than by the judicial branch.” Id. A court’s decision to invoke the primary
2 jurisdiction doctrine “does not indicate that it lacks jurisdiction.” Id.

3 Courts generally look to four factors in evaluating the propriety of the primary jurisdiction
4 doctrine: “(1) the need to resolve an issue that (2) has been placed by Congress within the
5 jurisdiction of an administrative body having regulatory authority (3) pursuant to a statute that
6 subjects an industry or activity to a comprehensive regulatory authority that (4) requires expertise
7 or uniformity in administration.” Syntek Semiconductor Co., Ltd. v. Microchip Tech. Inc., 307
8 F.3d 775, 781 (9th Cir. 2002). However, the doctrine is only appropriate if a claim “requires
9 resolution of an issue of first impression, or of a particularly complicated issue that Congress has
10 committed to a regulatory agency,” and if “protection of the integrity of a regulatory scheme
11 dictates preliminary resort to the agency which administers the scheme.” Brown v. MCI
12 WorldCom Network Servs., 277 F.3d 1166, 1172 (9th Cir. 2002) (quoting United States v. Gen.
13 Dynamics Corp., 828 F.2d 1356, 1362 (9th Cir. 1987)). Also crucial is “whether application will
14 enhance court decision-making and efficiency by allowing the court to take advantage of
15 administrative expertise.” Chabner v. United of Omaha Life Ins. Co., 225 F.3d 1042, 1051 (9th
16 Cir. 2000). For example, the Ninth Circuit has approved of district courts’ invocation of the
17 doctrine “where it is unclear whether a federal statute applies to a new technology.” Clark, 523
18 F.3d at 1115.

19 Though the question of which reference amount requirement applies to Parkay Spray
20 might narrowly be described as one of first impression, the same could be said of challenges to
21 any food product that is not already explicitly listed in the regulations. In enacting the NLEA,
22 Congress intended for FDA to “have the first word” with respect to reference amounts and serving
23 sizes. See United States v. Culliton, 328 F.3d 1074, 1082 (9th Cir. 2003). And FDA had the first
24 word in promulgating the relevant regulations and publishing its guide to NLEA requirements (in
25 1994), which establish the boundaries of the product categories in 21 C.F.R. § 101.12(b)(2). The
26 issues raised by the Complaint can be answered by applying those regulations in a straightforward
27 manner. The primary jurisdiction doctrine “does not require that all claims within an agency's
28

1 purview be decided by the agency. Nor is it intended to ‘secure expert advice’ for the courts from
2 regulatory agencies every time a court is presented with an issue conceivably within the agency's
3 ambit.” Brown, 277 F.3d at 1172. Though the doctrine plays an important role in “limited
4 circumstances,” it is not meant to immunize litigants from liability based on state law claims
5 whenever interpretation of federal regulations is required.

6 Moreover, a stay of these proceedings, or, as ConAgra seeks, a dismissal, would do little to
7 enhance the uniform administration of the NLEA, or to enhance the court’s decision-making or
8 efficiency, and it would needlessly frustrate “the historic primacy of state regulation of matters of
9 health and safety.” Lohr, 518 U.S. at 485. See, e.g., Chavez v. Blue Sky Natural Beverage Co.,
10 268 F.R.D. 365, 375 (N.D. Cal. 2010) (state law consumer protection claims based on misleading
11 food labeling regarding geographic origin of the product did not “threaten the integrity of the
12 FDA's regulatory scheme governing misbranded food and do not implicate technical and policy
13 questions that are reserved for the FDA”); Lockwood v. Conagra Foods, Inc., 597 F. Supp. 2d
14 1028, 1035 (N.D. Cal. 2009) (claims based on misleading use of the term “all natural” in food
15 products were not subject to primary jurisdiction doctrine because “this is not a technical area in
16 which the FDA has greater technical expertise than the courts — every day courts decide whether
17 conduct is misleading”).

18 The FDA’s expertise and uniform administration of the nation’s food labeling laws is not
19 required in order to determine whether Parkay Spray is more like sprayable oil or liquid butter for
20 purposes of serving size requirements. That question may be answered through the
21 “straightforward interpretation” of FDA regulations. Brown, 277 F.3d at 1173 (reversing and
22 remanding dismissal based on primary jurisdiction doctrine). ConAgra’s motion to dismiss on the
23 basis of the primary jurisdiction doctrine is therefore DENIED.

24 **C. Fraud Allegations**

25 ConAgra also moves to dismiss Plaintiff's claims for violation of the UCL, violation of the
26 CLRA, unjust enrichment, fraud by concealment, and and intentional misrepresentation, all on the
27 grounds that Plaintiff’s Complaint fails to plead fraud with particularity pursuant to Federal Rule
28

1 of Civil Procedure 9(b). Particularly, ConAgra contends that Plaintiff has failed to plead either
2 deception or reliance. With regard to the element of deceit, ConAgra argues that "Plaintiff has not
3 set forth with particularity any explanation of how the Parkay Spray label statements were false or
4 misleading." With regard to the element of reliance, ConAgra contends that Plaintiff "does not
5 allege how she was misled" by Parkay Spray's zero fat and zero calorie statements and nutrition
6 labeling.

7 The Complaint alleges that Plaintiff purchased Parkay Spray because she believed it was
8 free of fat and calories, based on Defendant's statements about the product; that the statements
9 were not true; and that she would not have purchased the product if she had known the statements
10 were not true. These allegations are sufficient to satisfy Rule 9(b). ConAgra's suggestion that
11 Plaintiff should have alleged "what serving size she claims is proper or the quantities in which she
12 used the product" ignores the allegation that, no matter the serving size, or in what quantities she
13 used Parkay Spray, Plaintiff alleges that she understood from ConAgra's labeling and marketing
14 that the product did not contain fat or calories.

15 ConAgra's argument that Plaintiff fails adequately to plead the reasonable consumer
16 standard because her belief that Parkay Spray contained no fat or calories was "idiosyncratic"
17 fares no better. Plaintiff alleges that over forty percent of Parkay Spray's 226 grams are grams of
18 fat, even though the product claims to be fat free. The bottle, she alleges, contains 832 calories,
19 even though it claims to contain none. The Complaint reproduces customer complaints other than
20 Plaintiff's own as well, each of which evidences that consumers were deceived by ConAgra's
21 labeling and marketing.

22 Plaintiff has adequately pled her fraud allegations, and the question of whether she can
23 prove them is not for the court to decide at this juncture. See, e.g., Williams v. Gerber Products
24 Co., 552 F.3d 934, 939 (9th Cir. 2008) (reversing dismissal of consumer protection, fraud, and
25 warranty claims based on misleading fruit snack labeling); Khasin v. Hershey Co., No. 12-cv-
26 01862-EJD, 2012 WL 5471153, at *8 (N.D. Cal. Nov. 9, 2012) (denying motion to dismiss fraud
27 claims based on health claims made on chocolate products; noting "the existence of questions of
28

1 fact with regards to Plaintiff's allegations of fraud or misrepresentation does not render the
2 pleadings inadequate").

3 **D. Consumer Protection Causes of Action**

4 Without citing to relevant authority, ConAgra seeks dismissal on the basis of the Supreme
5 Court's decisions in Iqbal, supra, 556 U.S. at 679, and Twombly, supra, 550 U.S. at 570, of
6 Plaintiff's seventh cause of action, which asserts on behalf of a nationwide class of Parkay Spray
7 customers claims for violation of the consumer protection statutes of forty-eight states and the
8 District of Columbia. ConAgra argues that "Plaintiff's laundry list referring to consumer
9 protection acts . . . comprises precisely the type of threadbare and formulaic allegations that are
10 insufficient." Opp. p. 15. ConAgra complains that "Plaintiff has failed to even include a
11 formulaic recitation of the elements of those claims, and she has failed to allege any facts
12 indicating that she would have a claim based on the law of states other than California." Id.

13 The Motion misapprehends Iqbal and Twombly. Plaintiff is required to plead "enough
14 facts to state a claim to relief that is plausible on its face." Twombly, 550 U.S. at 570 (emphasis
15 added). "A claim has facial plausibility when the plaintiff pleads factual content that allows the
16 court to draw the reasonable inference that the defendant is liable for the misconduct alleged."
17 Iqbal, 556 U.S. at 678. Plaintiff has satisfied that standard here. If ConAgra believed that
18 Plaintiff failed to state a claim under one or more state consumer protection statutes, they were
19 free to make that argument in their motion; but the fact that Plaintiff asserts claims under fifty
20 consumer protection statutes rather than just one is not a basis, in and of itself, for dismissal.
21 Defendant's motion to dismiss the seventh cause of action is therefore DENIED.

22 **E. Breach of Express Warranty**

23 A plaintiff asserting a breach of warranty claim must allege facts sufficient to show that
24 (1) the seller's statements constitute an affirmation of fact or promise or a description of the goods;
25 (2) the statement was part of the basis of the bargain; and (3) the warranty was breached. See
26 Weinstad v. Dentsply Int'l, Inc., 180 Cal. App. 4th 1213, 1227 (2010). In California, a breach of
27 express warranty claim is governed by Section 2313 of the Uniform Commercial Code. Id. Proof
28

1 of reliance on specific promises is not required. Id.

2 Courts in this district have previously found that plaintiffs stated express warranty claims
3 based on allegedly misleading food labeling. See, e.g., Brown v. Hain Celestial Grp., Inc., 11-cv-
4 03082-LB, 2012 WL 6697670, at *16 (N.D. Cal. Dec. 22, 2012) (“All Natural & Organic”
5 cosmetic products); Vicuna v. Alexia Foods, Inc., 11-cv-6119-PJH, 2012 WL 1497507, at *2
6 (N.D. Cal. Apr. 27, 2012) (“All natural” potato products).

7 ConAgra relies on two decisions in which misleading food label warranty claims were
8 dismissed because food labels do not constitute express warranties against a product defect. See
9 Maxwell v. Unilever U.S., Inc., 12-cv-01736-EJD, 2013 WL 1435232, at *4 (N.D. Cal. Apr. 9,
10 2013); Hairston v. S. Beach Beverage Co., Inc., 12-cv-1429-JFW, 2012 WL 1893818, at *5 (C.D.
11 Cal. May 18, 2012). Neither decision applies here; in each case, the warranty claims arose under
12 the Magnuson-Moss Warranty Act, 15 U.S.C. § 2301, et seq., and California’s Song-Beverly
13 Consumer Warranty Act, Cal. Civ. Code § 1790, et seq., which provide private rights of action for
14 breaches of express warranties, defined more narrowly than common law breach of warranty.³ In
15 particular, those acts require that the manufacturer warrant that the product is free from defects.
16 See 15 U.S.C. § 2301(6)(A); Cal. Civ. Code § 1791.2(a)(1).

17 Plaintiff alleges that ConAgra affirmatively described Parkay Spray as “fat free” and
18 “calorie free,” and that the description was part of the basis of the bargain. Because Plaintiff has
19 plausibly alleged that Parkay Spray is not fat free or calorie free, Plaintiff adequately states a claim
20 for common law breach of express warranty. ConAgra’s motion to dismiss on that basis is
21 therefore DENIED.

22 **F. Unjust Enrichment**

23 ConAgra is correct that in California there is no standalone cause of action for unjust
24 enrichment. “Rather, unjust enrichment is a basis for obtaining restitution based on quasi-contract
25

26 ³ This Court has recently recognized that a plaintiff cannot state a claim under the Magnuson-
27 Moss Warranty Act or the Song-Beverly Act on facts similar to those presented here. See Clancy
28 v. The Bromley Tea Co., 12-CV-03003-JST, 2013 WL 4081632 (N.D. Cal. Aug. 9, 2013).

1 or imposition of a constructive trust.” Myers–Armstrong v. Actavis Totowa, LLC, 382 Fed. Appx.
2 545, 548 (9th Cir.2010) (unpublished) (citing McKell v. Washington Mut., Inc., 142 Cal.App.4th
3 1457, 1489, 49 Cal.Rptr.3d 227, 254(2006); see also Hill v. Roll Intl. Corp., 195 Cal. App. 4th
4 1295, 1307, 128 Cal.Rptr.3d 109 (2011). Plaintiff has no such claims. Moreover, she is already
5 seeking restitution as part of her UCL claim, Compl. ¶ 104. ConAgra’s motion regarding this
6 claim is GRANTED and the claim is DISMISSED WITH PREJUDICE.

7 **G. Motion to Transfer**

8 Upon motion, for the convenience of the parties and witnesses, and in the interests of
9 justice, district courts may, in their discretion, transfer any civil action to any other district where
10 it might have been brought pursuant to 28 U.S.C. § 1404(a). Ninth Circuit courts evaluate several
11 factors in considering a motion to transfer, including the plaintiff’s choice of forum, the contacts
12 relating to the plaintiff’s cause of action in the chosen forum, the parties’ contacts with the forum,
13 the availability of compulsory process to compel attendance of unwilling non-party witnesses, the
14 differences in costs of litigation in the two forums, the ease of access to sources of proof, the
15 location where the relevant agreements were negotiated or executed, and the state most familiar
16 with governing law. See Jones v. GNC Franchising, Inc., 211 F.3d 495, 498–99 (9th Cir. 2000).
17 The statute calls for an “individualized, case-by-case consideration of convenience and fairness.”
18 Stewart Org. v. Ricoh Corp., 487 U.S. 22, 29 (1988).

19 ConAgra moves to transfer this action to the District of Nebraska because a different
20 plaintiff represented by one of Plaintiff’s attorneys filed and then dismissed an action in Nebraska
21 prior to the filing of the instant Complaint, and because ConAgra is based in Nebraska. The court
22 is not persuaded that the convenience of the parties or the interests of justice require transfer.

23 Fundamental to federal law is the axiom that the plaintiff is master of the complaint. See
24 City of Chicago v. Int’l Coll. of Surgeons, 522 U.S. 156, 164 (1997) (citing Caterpillar Inc. v.
25 Williams, 482 U.S. 386, 398 (1987)). ConAgra argues that Plaintiff’s choice of forum is entitled
26 to less deference here because she proposes a class action. “Although great weight is generally
27 accorded plaintiff’s choice of forum, when an individual brings a derivative suit or represents a
28

1 class, the named plaintiff's choice of forum is given less weight.” Lou v. Belzberg, 834 F.2d 730,
2 739 (9th Cir. 1987)(citations omitted).

3 Next, ConAgra argues that plaintiff’s choice of forum should be discounted because “there
4 is a suggestion of forum shopping.” Opp. p. 20 (quoting Jovel v. i-Helath, Inc., 2012 WL
5 5470057, at *4 (C.D. Cal. Nov. 8, 2012). On this point, the Court is less persuaded. A now-
6 dismissed action in another district, brought by a different plaintiff, has no bearing on the
7 convenience of the parties or the interests of justice. Plaintiff is a California resident suing, in
8 part, under California law. Her choice of forum is proper. Relatedly, this court is obviously more
9 familiar with California law than an out-of-state district court. That factor too weighs against
10 transfer.

11 As for the relative contacts of the parties to the forums, although Plaintiff is a resident of
12 California, that fact does not weigh particularly heavily. As a colleague court recently observed,

13 Although Plaintiff would have some role in a trial, it would not be nearly as
14 significant as that of Defendant, its executives, and its scientists. Indeed, it is not
15 clear to the court what Plaintiff would testify about beyond the fact of her purchase,
16 since the gravamen of the Complaint is the falsity of the claims on the package,
17 which would not be a subject of Plaintiff’s testimony.
18 Jovel, 2012 WL 5470057, at *3. On the other hand, ConAgra’s claim to its putative home forum
19 of Nebraska is equally weak. Parkay Spray is sold and marketed nationally. The District of
20 Nebraska has no greater and no lesser relationship to Plaintiff’s claims than this one. In addition,
21 although ConAgra’s headquarters are in Nebraska, it identifies no specific witnesses who are
22 located there. The parties are both represented by law firms with nationwide offices. ConAgra
23 itself has offices nationwide, as it explains in its motion and accompanying declarations. And
24 because party witnesses need not travel for deposition, and discovery will inevitably be exchanged
25 electronically, ConAgra’s claims of inconvenience are not persuasive. Finally, ConAgra does not
26 identify any non-party witnesses relevant to this action that would weigh in favor of transfer.

27 Taking all the factors into account, ConAgra fails to establish that the convenience of the
28 parties and witnesses, and the interests of justice, require transfer. The court, in its discretion,
therefore DENIES the motion.


1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28

V. CONCLUSION

For the foregoing reasons, the Court hereby GRANTS the motion as to Plaintiff’s claim for unjust enrichment, and that claim is DISMISSED WITHOUT LEAVE TO AMEND. The Court DENIES ConAgra’s Motion to Dismiss as to Plaintiff’s remaining claims, and DENIES Defendant’s Motion to Transfer.

IT IS SO ORDERED.

Dated: September 2, 2013



JON S. TIGAR
United States District Judge